Tranexamic Acid USP/EP
Pharmaceutical USP/EP
Pharmaceutical API

Tranexamic Acid USP/EP

High-purity pharmaceutical grade Tranexamic Acid manufactured under stringent cGMP conditions. This antifibrinolytic API is essential for hemostatic therapy, particularly in bleeding control during surgery and trauma care, providing reliable quality and regulatory compliance.

  • USP/EP Grade Pharmaceutical API
  • cGMP Manufacturing Standards
  • ≥99.0% Purity (HPLC)
  • Comprehensive COA Documentation
  • Antifibrinolytic for Bleeding Control
  • Regulatory Compliance Ready
Request Quote Technical Support

Technical Specifications

Chemical Formula: C8H15NO2
CAS Number: 1197-18-8
EINECS Number: 214-818-2
Molecular Weight: 157.21 g/mol
Physical State: White crystalline powder
Purity (HPLC): ≥99.0% (USP/EP Grade)
pH (1% solution): 6.5-7.5
Loss on Drying: ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤0.5% (total impurities)
Solubility: Freely soluble in water
Storage Conditions: Store at room temperature, protect from light
Shelf Life: 3 years from date of manufacture
Packaging Options: 25g, 50g, 100g pharmaceutical containers

Applications

Oral Tablet Formulations
Injectable Formulations
Hemostatic Therapy
Surgical Bleeding Control
Antifibrinolytic Therapy
Trauma Surgery
Fibrinolysis Inhibition
Bleeding Disorders
Hematology Research
Clinical Surgery
Regulatory Submissions
Reference Standards

Industry-Specific Grades

DRAVYOM offers specialized Tranexamic Acid grades tailored for specific hemostatic pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse bleeding control therapeutic applications.

USP Grade (United States Pharmacopeia)
Purity: ≥99.0% (HPLC) Related Substances: ≤0.5% Heavy Metals: ≤10 ppm Application: FDA-compliant formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.0% (HPLC) pH: 6.5-7.5 (1% solution) Loss on Drying: ≤0.5% Application: EU regulatory submissions
Hemostatic Grade
Purity: ≥99.5% (HPLC) Fibrinolysis Activity: Verified Endotoxin: ≤0.25 EU/mg Application: Surgical hemostasis
Injectable Grade
Purity: ≥99.8% (HPLC) Sterility: Compliant Particulate Matter: <25 µm Application: Injectable formulations

Quality Standards

DRAVYOM's Tranexamic Acid is manufactured under stringent quality control protocols, meeting international pharmaceutical standards including USP, EP specifications. Our hemostatic-grade production ensures consistent performance and regulatory compliance.

ISO 9001:2015 Certified Manufacturing
USP/EP Grade Specifications
≥99.0% HPLC Purity
Advanced Hemostatic Testing
Antifibrinolytic Grade
Batch-to-Batch Consistency
Comprehensive COA
Pharmaceutical Grade Packaging

Advanced Chemical Properties & Performance

Tranexamic Acid exhibits exceptional antifibrinolytic properties essential for hemostatic applications. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding coagulation disorder treatments.

Molecular Properties
Molecular Weight: 157.21 g/mol
LogP: -2.3
pKa: 4.3, 10.8
Bioavailability: 34-50%
Physical Properties
Melting Point: 205-207°C
Solubility (Water): 16.5 g/100 mL
Crystalline Form: Stable crystalline acid
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
Plasmin Ki: 7 μM
Plasminogen Binding: High affinity
Selectivity: Antifibrinolytic
Stability: Stable in solid state
Purity Specifications
Assay: ≥99.0%
Related Substances: ≤0.5%
Heavy Metals: ≤10 ppm
Residual Solvents: ICH Q3C compliant
Stability Properties
Shelf Life: 5 years (unopened)
Light Sensitivity: Not light sensitive
Temperature Stability: Stable at room temperature
pH Stability: Stable pH 2-8

Performance Characteristics

Detailed performance metrics demonstrate Tranexamic Acid superiority in hemostatic applications with exceptional antifibrinolytic activity, bioavailability, and reproducibility across diverse coagulation treatment formulations.

Antifibrinolytic Activity

Plasmin Ki: 7 μM

Effective clot stabilization
Bioavailability

Oral: 34-50% bioavailability

Reliable systemic exposure
Stability

Solid state: >5 years stability

Long-term pharmaceutical integrity
Thermal Stability

Working range: 15-40°C processing

Stable during formulation
Batch Reproducibility

Variation: ±0.5% between batches

Consistent lot-to-lot performance
Shelf Stability

5 years under proper storage conditions

Extended pharmaceutical grade integrity

Safety Information

Pharmaceutical grade hemostatic API requiring careful handling. Handle with appropriate protective equipment in controlled environments. Avoid skin contact and inhalation. Follow cGMP guidelines for pharmaceutical APIs and ensure proper waste disposal procedures.

Pharmaceutical API
Avoid Skin Contact
Avoid Inhalation

Storage & Handling

Store in original sealed containers in a cool, dry, well-ventilated area away from light and moisture. Keep containers tightly closed and protect from direct sunlight. Use appropriate containment measures for pharmaceutical API handling.

Room temperature storage (15-25°C)
Protect from moisture
Original sealed containers
Pharmaceutical containment required

Chemical Mechanisms & Reaction Pathways

Tranexamic Acid functions as a competitive plasmin inhibitor through lysine analog binding, preventing fibrinolysis and enabling precise hemostatic interventions with well-characterized antifibrinolytic pathways and coagulation mechanisms.

Plasmin Inhibition

Competitive inhibition of plasmin through lysine-binding site occupation

Prevents fibrin clot dissolution
Plasminogen Binding

Reversible binding to plasminogen preventing conversion to plasmin

Blocks fibrinolytic activation pathway
Renal Clearance

Primary renal elimination with minimal hepatic metabolism

Predictable pharmacokinetic profile
Therapeutic Action

Dose-dependent antifibrinolytic effect reducing bleeding complications

Preserves hemostatic balance effectively

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical manufacturing access with complete documentation packages supporting international standards and pharmaceutical development requirements.

USP/EP Standards

United States Pharmacopeia and European Pharmacopoeia compliance

ICH Guidelines

International Conference on Harmonisation pharmaceutical standards

cGMP Manufacturing

Current Good Manufacturing Practice certified production

Global Registration

DMF filings and regulatory support for worldwide markets

Stability Studies

Long-term and accelerated stability data packages

Impurity Profiling

Comprehensive impurity identification and qualification

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, analytical method development, and regulatory assistance to optimize pharmaceutical manufacturing processes and ensure successful product development.

Formulation Development
  • API compatibility studies
  • Excipient interaction analysis
  • Stability-indicating method development
  • Formulation optimization support
Analytical Services
  • Method validation and transfer
  • Impurity profiling and identification
  • Forced degradation studies
  • Bioanalytical method development
Technical Support
  • Pharmaceutical development consultation
  • Manufacturing process optimization
  • Quality system implementation
  • Regulatory filing support
Supply Solutions
  • Clinical trial material supply
  • Commercial scale manufacturing
  • Just-in-time delivery programs
  • Global supply chain management

Environmental Impact & Sustainability

Our pharmaceutical API production emphasizes environmental responsibility through sustainable manufacturing practices, waste minimization, and comprehensive environmental impact management for pharmaceutical operations.

Green Chemistry

Optimized synthetic routes with minimal environmental impact

Solvent Recovery

Advanced solvent recovery and recycling systems

Energy Efficiency

Renewable energy integration in manufacturing processes

Waste Management

Comprehensive pharmaceutical waste treatment protocols

ISO 14001

Environmental management system certified operations

Packaging Innovation

Sustainable packaging materials and design optimization

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced process control technology and comprehensive quality systems to ensure consistent API quality and performance across all production batches.

cGMP Manufacturing

Current Good Manufacturing Practice compliant production in controlled environments

FDA and EMA inspected pharmaceutical facilities
Quality Control

Multi-point quality control testing including assay, related substances, and residual solvents

HPLC, GC-MS, and NMR analytical verification
Quality Systems

ISO 9001:2015 quality management with pharmaceutical quality system standards

Continuous improvement and change control procedures
Packaging Systems

Primary packaging in controlled atmosphere with tamper-evident sealing

Light protection and moisture barrier packaging

Market Applications & Performance Data

Comprehensive pharmaceutical development data demonstrating API effectiveness across diverse therapeutic applications with quantified performance metrics and regulatory validation studies.

Pharmaceutical Manufacturing
Purity: >99.5% pharmaceutical grade Stability: 36-month shelf life data Compliance: 100% regulatory specifications
Research & Development
Research Support: 200+ published studies Method Validation: Cross-platform verification Innovation: Advanced analytical techniques
Clinical Applications
Clinical Grade: Phase I-III trial supply Regulatory Success: Global market approvals Manufacturing: Scalable production processes

DRAVYOM Competitive Advantages

Pharmaceutical Excellence

Consistently exceeds USP/EP specifications with exceptional purity and pharmaceutical performance standards

Reliable Supply Chain

Guaranteed pharmaceutical-grade availability with strategic inventory management and production scheduling

Development Expertise

Dedicated pharmaceutical development team provides formulation and analytical method support

Regulatory Excellence

Comprehensive documentation packages with global regulatory filing support and validation

Global Standards

International compliance with USP, EP, JP, and ICH guidelines for worldwide pharmaceutical acceptance

Partnership Excellence

Collaborative pharmaceutical development relationships with custom API synthesis and scale-up services